检测慢性肝病患者血清中CA19-9的临床意义  

Clinical Significance of Determination Serum CA19-9 in Patients with Chronic Liver Disease

作　　者：陈宏斌[1] 张娅东[1] 李建军[1] 黄跃[1] 

机构地区：[1]福建省三明市第一医院,365000

出　　处：《中西医结合肝病杂志》2001年第4期202-203,共2页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:探讨血清CA19-9对原发性肝癌(简称肝癌)及肝硬化患者的临床诊断价值。方法:用IRMA法检测134例患者及40例健康人员血清CA19-9水平。结果:肝癌组患者血清CA19-9均值为232.4±113.5U几,肝硬化组为82.6±34.3U/L,慢性肝炎组为10.2±3.6U/L,正常对照组为9.8±4.3U/L,其组间比较有非常显著性差异(P<0.01)。血清CA19-9的阳性检出率肝癌患者为73.8％(31/42)、肝硬化患者为39.3％(22/36)、慢性肝炎患者为5.5％(2/36),其组间比较均有显著性差异(P<0.01)。结论:血清CA19-9有助于肝癌及肝硬化的诊断,可作为诊断肝癌及肝硬化的一项辅助性检测指标。To study the clinical diagnostic value of serum carbohydrate antigen 19-9 (CA19-9) in patients with liver carcinoma and cirrhosis. Methods: Patients with liver carcinoma 42. 56 cirrhosis, 36 chronic hepatitis and 40 healthy controls were detected the levels of serum CA19-9 by using IRMA methods. Results: The levels of serum CA19-9 in liver cancer group was 232. 4±113. 5U/L, cirrhosis group was 82. 6±34. 3U/L, chronic hepatitis was 10. 2±3. 6U/ L, and the healthy controls group was 9. 8±4. 3U/L. Amount of it liver carcinoma group was singnificantly highter than that in cirrhosis group, Chronic hepatitis group and normal controls group (P<0. 01). In cirrhosis group it was also singnificntly highter than in chronic heaptitis group and healthy controls group (P<0.01). But there was no difference between chronic hepatitis group and normal controls group (P>0. 05). When 29U/L was taken as the cutoff value the positive rate in liver cancer group was 73. 8 (31/42), cirrhosis group was 39. 3% (22/36), chronic hepatitis group was 5. 5% (2/36),normal controls group was 0% (0/40). Liver carcinoma group was significantly highter than that in cirrhosis group, chronic hepatitis group and normal controls (P<0.001). In cirrhosis group it was also singnificantly highter than that in chronic heaptitis group and normal controls group (P<0. 01). But there was no difference between chronic hepatitis group and normal controls group (P>0. 05). We also found there was a positive correlation between serum CA19-9 and γ-GT(r = 0. 84,P<0. 01). Conclusion:Serum CA19-9 may help for the diagnosis of patients with liver carcinoma and cirrhosis, and can be used as an adjuvant indices to diagnose liver carcinoma and cirrhosis.

关 键 词：慢性肝脏疾病 免疫 CA19-9抗原 诊断 

分 类 号：R575[医药卫生—消化系统]